GSK reports strong Q3 2026 financial results in US dollars
Unaudited data shows $33.4 billion turnover and $5.9 billion operating profit for the first nine months of 2026.
See the latest news and media coverage for GSK. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing medicines and vaccines
gsk.comLast updated
In short: GSK secured FDA approvals for Jemperli and Hibsago amid strong oncology data.
Unaudited data shows $33.4 billion turnover and $5.9 billion operating profit for the first nine months of 2026.
Bepirovirsen enables functional cures. GSK plans further submissions.
This immunotherapy enables patients with MSI-H/dMMR tumors to potentially avoid chemotherapy, radiation, and surgery.
The document reaffirms full-year 2026 financial targets, highlighting the impact of the Nuvalent acquisition on interest charges and tax rates.
GSK (LSE:GSK) has released third quarter figures that present a mixed picture. Sales reached £8,887...
GSK (GSK) stock toppled Wednesday after the British drugmaker reported adjusted earnings of $1.45 per share on $11.83 billion in third-quarter sales, according to FactSet...
GSK beat Q3 analyst consensus with $1.47 adjusted EPS and $11.95 billion revenue, as specialty drugs...
One-off charges, led by £328 million of Accelerate Growth restructuring, pushed adjusted earnings be...
Track GSK and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to GSK and other trending companies.